Urokinase is approved as a thrombolytic for which conditions?

Urokinase is primarily indicated as a thrombolytic agent for the treatment of pulmonary embolism and coronary artery thrombosis. It works effectively by dissolving blood clots that obstruct blood flow in these conditions. In patients with pulmonary embolism, urokinase can help restore blood flow in the lungs, which is critical for oxygenation and overall cardiovascular function. Similarly, in cases of coronary artery thrombosis, it aids in dissolving the clots that can result in myocardial ischemia, thereby reducing the risk of heart damage or heart attacks.

The other conditions mentioned in the options are either not the primary indications for urokinase or do not apply to its approved uses. For instance, while strokes and deep vein thrombosis are conditions requiring thrombolytic therapy, urokinase is not the preferred treatment for these. Thrombolytics that are more commonly used include alteplase for stroke, and for deep vein thrombosis, anticoagulants are typically employed over thrombolytic therapy. Additionally, urokinase is not indicated for cardiac arrest or aneurysms, as these conditions involve different therapeutic approaches.